Literature DB >> 30630068

Diffusion-weighted imaging of the dentate nucleus after repeated application of gadolinium-based contrast agents in multiple sclerosis.

Philipp Eisele1, Kristina Szabo2, Anne Ebert2, Alexander Radbruch3, Michael Platten2, Stefan O Schoenberg4, Achim Gass2.   

Abstract

OBJECTIVE: Over the last years several studies reported an increased signal intensity (SI) of the dentate nucleus (DN) on unenhanced T1-weighted images after repeated application of gadolinium-based contrast agents (GBCAs), suggesting gadolinium deposition. The aim of this study was to investigate with diffusion-weighted MRI possible tissue abnormalities of the DN in multiple sclerosis (MS) patients.
MATERIAL AND METHODS: We retrospectively identified seventeen patients with at least six contrast-enhanced MRI examinations by using the linear GBCA gadopentate dimeglumine and twenty-three patients with the exclusive use of the macrocyclic contrast agent gadoterate meglumine followed by another 3 Tesla MRI scan including unenhanced T1-weighted and diffusion-weighted images.
RESULTS: In the linear GBCA group, we found significant differences of the DN-to-pons SI ratio on unenhanced T1-weighted images (1.13 ± 0.05) when compared to the macrocyclic GBCA group (0.97 ± 0.03; p < 0.001). However, we found no significant differences between apparent diffusion coefficient (ADC) values of the DN in both groups (linear GBCA group: 0.82 ± 0.04 × 10-3 mm/s2; marcocyclic GBCA group: 0.79 ± 0.04 × 10-3 mm/s2; p = 0.15).
CONCLUSIONS: Our results do not suggest that there is any difference in ADC values in the T1-hyperintense DN, which does not indicate a difference in tissue integrity between patients exposed to macrocyclic or linear GBCAs.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ADC; Dentate nucleus; Diffusion; Gadolinium; MRI

Mesh:

Substances:

Year:  2019        PMID: 30630068     DOI: 10.1016/j.mri.2019.01.007

Source DB:  PubMed          Journal:  Magn Reson Imaging        ISSN: 0730-725X            Impact factor:   2.546


  6 in total

1.  Gadolinium Deposition Safety: Seeking the Patient's Perspective.

Authors:  C A Mallio; C C Quattrocchi; À Rovira; P M Parizel
Journal:  AJNR Am J Neuroradiol       Date:  2020-05-07       Impact factor: 3.825

2.  Diffusion Tensor Imaging of the Dentate Nucleus After Repeated Administration of Gadobutrol in Children.

Authors:  Kerem Ozturk; David Nascene
Journal:  Cerebellum       Date:  2021-08-27       Impact factor: 3.648

3.  Cumulative gadodiamide administration leads to brain gadolinium deposition in early MS.

Authors:  Robert Zivadinov; Niels Bergsland; Jesper Hagemeier; Deepa P Ramasamy; Michael G Dwyer; Ferdinand Schweser; Channa Kolb; Bianca Weinstock-Guttman; David Hojnacki
Journal:  Neurology       Date:  2019-07-08       Impact factor: 11.800

4.  Visible T1-hyperintensity of the dentate nucleus after multiple administrations of macrocyclic gadolinium-based contrast agents: yes or no?

Authors:  Alessandra Splendiani; Antonella Corridore; Silvia Torlone; Milvia Martino; Antonio Barile; Ernesto Di Cesare; Carlo Masciocchi
Journal:  Insights Imaging       Date:  2019-09-04

5.  Prospective Multicenter Study of the Safety of Gadoteridol in 6163 Patients.

Authors:  Sung Bum Cho; A-Leum Lee; Hyuk Won Chang; Kyeong Ah Kim; Won Jong Yoo; Jeong A Yeom; Myung Ho Rho; Sung Jin Kim; Yun-Jung Lim; Miran Han
Journal:  J Magn Reson Imaging       Date:  2019-10-29       Impact factor: 4.813

6.  Anterior pituitary gland T1 signal intensity is influenced by time delay after injection of gadodiamide.

Authors:  Carlo A Mallio; Laura Messina; Marco Parillo; Gianguido Lo Vullo; Bruno Beomonte Zobel; Paul M Parizel; Carlo C Quattrocchi
Journal:  Sci Rep       Date:  2020-09-11       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.